✦ LIBER ✦

Advanced glycosylation end products: A new disease marker for diabetes and aging

✍ Scribed by James T. Wu

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 339 KB
Volume: 7
Category: Article
ISSN: 0887-8013
DOI: 10.1002/jcla.1860070503

No coin nor oath required. For personal study only.

✦ Synopsis

Advanced glycosylation end products (AGEs) are a potentially useful marker for monitoring glycemic control, predicting the risk of diabetes-and aging-associated clinical complications, and monitoring the treatment of patients with micro-and macrovascular diseases, including retinopathy, atherosclerosis, nephropathy, and neuropathy. AGES or AGE-proteins are derived from nonenzymatically glycated proteins (Amadori products) after further cross-linking with other proteins and additional rearrangement. AGE-proteins can be assayed by either radioreceptor or immunoassays in blood and tissues. No commercial kit is available at this time.

📜 SIMILAR VOLUMES

Are advanced glycation end-products spec

Are advanced glycation end-products specific biomarkers for Alzheimer's disease?

✍ M. Staniszewska; J. Leszek; K. Małyszczak; A. Gamian 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB

Accumulation of advanced glycation end p

Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis

✍ Jeroen DeGroot; Nicole Verzijl; Marion J. G. Wenting-Van Wijk; Kim M. G. Jacobs; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Objective: Osteoarthritis (oa) is one of the most prevalent and disabling chronic conditions affecting the elderly. its etiology is largely unknown, but age is the most prominent risk factor. the current study was designed to test whether accumulation of advanced glycation end products (ages), w

Advanced glycosylation end products (AGE

Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with Type 2 diabetes mellitus

✍ Ma. Eugenia Garay-Sevilla; Laura Eugenia Nava; Juan Manuel Malacara; Kazimierz W 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

Background Advanced glycosylation end product (AGE) formation is a major mechanism for the development of complications in diabetes, and the possible roles of insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3) are not clearly established. ## Methods We examined the associati

Circulating advanced glycation end produ

Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes

✍ Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Takanori Matsui; Yayoi Kurit 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

Acute Kawasaki disease is associated wit

Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12

✍ Helmut Wittkowski; Keiichi Hirono; Fukiko Ichida; Thomas Vogl; Fei Ye; Xing Yanl 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Abstract ## Objective Receptor for advanced glycation end products (RAGE) serves as a pattern recognition receptor for several endogenous ligands that are potent inducers of inflammation. By activating endothelial cells and leukocytes, RAGE augments recruitment of leukocytes to sites of inflamm